Branchburg, NJ, United States of America

Danqing D Feng

This inventor holds 32 USPTO granted patents and 8 published patent applications, plus 3 CIPO patents and 19 EPO patents, primarily in Diabetes Treatment. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Merck Shapr & Dohme Corp.. Active years: 2000-2025.

USPTO Granted Patents = 32 (Patent Applications = 8)

% Patents Active = 96.9

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 19 (Patent Applications = 19)

Average Co-Inventor Count = 6.5

ph-index = 5

Forward Citations = 86(Granted Patents)

Location History:

Branchburg Township, NJ (US) (2001 - 2003)
Branchburg, NJ (US) (2000 - 2011)
Green Brook, NJ (US) (2010 - 2023)

Company Filing History:

21 out of 2,405

Merck Sharp + Dohme Corp.

Merck Shapr & Dohme Corp.

patent

4. 1 out of 834,453

Other

patents

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Insulin Delivery

Dipeptidyl Peptidase Inhibitors

Insulin Conjugates

Receptor Agonists

Aminotetrahydropyrans

Heterocyclic Compounds

Antiprotozoal Agents

Beta-Amino Heterocycles

Glucose Responsiveness

Azabenzimidazole Derivatives

Cyclic Compounds

Substituted Aminopiperidines

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12427187 - Glucose-responsive insulin conjugates (2025-09-30),

2. 11820805 - Conjugate based systems for controlled insulin delivery (2023-11-21),

3. 11041009 - Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes (2021-06-22),

4. 10800827 - Insulin receptor partial agonists (2020-10-13),

5. 10689430 - Insulin receptor partial agonists (2020-06-23),

6. 10183981 - Insulin receptor partial agonists (2019-01-22),

7. 10017556 - Insulin receptor partial agonists (2018-07-10),

8. 9868733 - Azabenzimidazole tetrahydrofuran derivatives (2018-01-16),

9. 9556193 - Benzimidazole hexahydrofuro[3,2-b]furan derivatives (2017-01-31),

10. 9540364 - Benzimidazole tetrahydrofuran derivatives (2017-01-10),

11. 9527839 - Benzimidazole tetrahydropyran derivatives (2016-12-27),

12. 9382243 - Azabenzimidazole tetrahydropyran derivatives (2016-07-05),

13. 9290517 - Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives (2016-03-22),

14. 8853212 - Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes (2014-10-07),

15. 8796258 - Cyclic azabenzimidazole derivatives useful as anti-diabetic agents (2014-08-05),

Title: **Innovative Contributions of Danqing D Feng in Insulin Delivery Systems**

Introduction

Danqing D Feng is a notable inventor residing in Branchburg Township, NJ, who has made significant strides in the field of biopharmaceuticals, specifically focusing on insulin delivery systems. With a total of 31 patents credited to his name, Feng's work continues to pave the way for innovations in diabetes treatment.

Latest Patents

Feng's latest patents include groundbreaking inventions such as "Conjugate Based Systems for Controlled Insulin Delivery" and "Glucose Responsive Insulin Comprising a Tri-valent Sugar Cluster for Treatment of Diabetes." The first patent discusses conjugates that consist of insulin molecules conjugated to multiple separate ligands, each containing a saccharide. This inventive framework allows for insulin to be administered in a manner sensitive to serum concentrations, potentially enhancing its efficacy. In his second patent, the insulin conjugate featuring a tri-valent sugar cluster demonstrates a pharmacokinetic profile that responds optimally to glucose levels, providing a sophisticated approach to managing diabetes without the need for exogenous binding molecules.

Career Highlights

Danqing D Feng has been associated with prestigious organizations such as Merck Sharp & Dohme Corporation and Merck & Company, Inc., where he has utilized his expertise to further research and development in medicinal chemistry and biopharmaceutical innovations. His contributions have significantly influenced the techniques and technologies used in insulin delivery systems.

Collaborations

Throughout his career, Feng has collaborated with esteemed colleagues, including Tesfaye Biftu and XiaoXia Qian. These partnerships have been instrumental in advancing research efforts and pushing the boundaries of what is possible in the field of diabetes treatment.

Conclusion

Danqing D Feng's innovative work in insulin delivery showcases a commitment to improving the lives of those affected by diabetes. His ongoing contributions through patents and collaborations reflect a dedication to advancing medical science and providing new solutions for patients worldwide. As the field of biopharmaceuticals continues to evolve, Feng's inventions are likely to play a critical role in shaping the future of diabetes management.